UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current standards for clinical management of small cell lung cancer

Translational lung cancer research, 2018-02, Vol.7 (1), p.69-79

2018

Volltextzugriff (PDF)

Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing

Cell, 2014-03, Vol.156 (6), p.1298-1311

2014

Volltextzugriff (PDF)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Journal of thoracic oncology, 2019-02, Vol.14 (2), p.237-244

2019

Volltextzugriff (PDF)

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

Immunity (Cambridge, Mass.), 2015-09, Vol.43 (3), p.579-590

2015

Volltextzugriff (PDF)

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Cancer discovery, 2019-10, Vol.9 (10), p.1372-1387

2019

Volltextzugriff (PDF)

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer

Translational lung cancer research, 2017-10, Vol.6 (5), p.550-559

2017

Volltextzugriff (PDF)

Identification of DHODH as a therapeutic target in small cell lung cancer

Science translational medicine, 2019-11, Vol.11 (517)

2019

Volltextzugriff (PDF)

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

Cell reports (Cambridge), 2017-12, Vol.21 (11), p.3298-3309

2017

Volltextzugriff (PDF)

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers

Future oncology (London, England), 2020-03, Vol.16 (9), p.417-425

2020

Volltextzugriff (PDF)

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

JCO precision oncology, 2017-01 (1), p.1-13

2017

Volltextzugriff (PDF)

Assembly of the Brainstem Cochlear Nuclear Complex Is Revealed by Intersectional and Subtractive Genetic Fate Maps

Neuron (Cambridge, Mass.), 2006-04, Vol.50 (2), p.205-218

2006

Volltextzugriff (PDF)

Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion

JCO precision oncology, 2018 (2), p.1-12

2018

Volltextzugriff (PDF)

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

NPJ precision oncology, 2021-08, Vol.5 (1), p.74-74, Article 74

2021

Volltextzugriff (PDF)

Targeting TRK family proteins in cancer

Pharmacology & therapeutics (Oxford), 2017-05, Vol.173, p.58-66

2017

Volltextzugriff (PDF)

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Clinical cancer research, 2019-12, Vol.25 (23), p.6958-6966

2019

Volltextzugriff (PDF)

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

Clinical cancer research, 2016-09, Vol.22 (18), p.4585-4593

2016

Volltextzugriff (PDF)

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Journal of clinical oncology, 2019-02, Vol.37 (4), p.278-285

2019

Volltextzugriff (PDF)

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Clinical cancer research, 2019-11, Vol.25 (22), p.6662-6670

2019

Volltextzugriff (PDF)

Hindbrain Rhombic Lip Is Comprised of Discrete Progenitor Cell Populations Allocated by Pax6

Neuron (Cambridge, Mass.), 2005-12, Vol.48 (6), p.933-947

2005

Volltextzugriff (PDF)

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Trends in pharmacological sciences (Regular ed.), 2019-05, Vol.40 (5), p.295-297

2019

Volltextzugriff (PDF)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2021-04, Vol.39 (11), p.1253-1263

2021

Volltextzugriff (PDF)

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Journal of thoracic oncology, 2020-04, Vol.15 (4), p.520-540

2020

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(90)

Sprache

Englisch
(89)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(47)
Oncology
(35)
Humans
(27)
Animals
(14)
Lung Neoplasms - Drug Therapy
(13)
Male
(13)
Middle Aged
(13)
Female
(12)
Aged
(11)
Lung Neoplasms - Genetics
(11)
Lung Neoplasms - Pathology
(11)
Adult
(10)
Respiratory System
(10)
Tumors
(9)
Mice
(8)
Small Cell Lung Carcinoma - Drug Therapy
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Lung Neoplasms - Metabolism
(7)
Aged, 80 And Over
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current standards for clinical management of small cell lung cancer

Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer

Identification of DHODH as a therapeutic target in small cell lung cancer

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1 -Positive Non–Small-Cell Lung Cancer

Assembly of the Brainstem Cochlear Nuclear Complex Is Revealed by Intersectional and Subtractive Genetic Fate Maps

Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Targeting TRK family proteins in cancer

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Hindbrain Rhombic Lip Is Comprised of Discrete Progenitor Cell Populations Allocated by Pax6

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Suchergebnisse filtern